SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics, has reported a busy and transformative 2025, positioning the company for significant growth in 2026. The company focused on expanding its market reach, differentiating its services, and optimizing pricing to enhance customer loyalty and repeat business.
Key achievements in 2025 include expanding its franchise network to 258 locations, a 15% year-over-year increase as of September 30, 2025. The company also revised pricing, resulting in a 5% sequential increase in average revenue per customer in the third quarter. New services, including plastic surgery and infertility treatment, were added to strengthen its market share. International expansion into Singapore and Thailand was initiated, with early 2026 marking the first U.S. expansion. SBC also launched new brands, "Neo Skin Clinic" and "Hada no Aozora Clinic," in Tokyo, integrating insurance-covered dermatology with private-pay aesthetic treatments.
Acquisitions played a key role in SBC's strategy. The company acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and Waqoo, a related subsidiary, to enhance R&D and integrate technologies in clinical areas such as AGA and orthopedics. Additionally, SBC was added to the Russell 3000 Index, increasing its visibility among institutional investors. The company also announced a stock buyback program of up to $5 million, reflecting confidence in its growth prospects.
With $125 million in cash at the start of the year, SBC made strategic acquisitions and laid groundwork for new markets. The company targeted Chinese cosmetic tourists by adding Chinese-speaking staff and promoting services on Chinese social media. In Singapore, SBC expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., and in Thailand, it signed an e-consulting agreement with BLEZ ASIA Co. Ltd. to support a new dermatology clinic in Bangkok.
The global cosmetic surgery market, valued at $122.08 billion in 2022, is expected to grow at a CAGR of 14.7% through 2030, and SBC Medical is well-positioned to capitalize on this demand. The company's focus on accessibility and advanced treatments, combined with its multi-brand strategy, aims to drive growth in 2026 and beyond.
